Zum Hauptinhalt springen

Structural retinal changes in cerebral small vessel disease

In: Scientific Reports, Jg. 12 (2022-12-01), Heft 1
Online unknown

Structural retinal changes in cerebral small vessel disease 

These authors contributed equally: S. Magdalena Langner and Jan H. Terheyden.

Introduction

Cerebral small vessel disease (CSVD) is associated with hypertension, hypercholesterolemia and obesity and a risk factor for stroke, vascular cognitive impairment and depression, thus contributing considerably to global mortality[1]–[3]. It is characterized by narrowing of the vessel lumen and failure of vascular autoregulation[3]. CSVD can be clinically silent, but is commonly associated with a decline in cognitive function with disease progression[4]–[6]. The lifetime probability to develop CSVD is substantial. For example, only 8% of the elderly general population in the Rotterdam study had no magnetic resonance imaging (MRI) changes suggestive of CSVD[2]. Prevalence data from other sources are similarly high[7].

Cerebral small vessels are difficult to assess using even high-resolution MRI. Thus, diagnostic markers used are downstream cerebral changes caused by the resulting ischemia including periventricular and subcortical white matter lesions (WML) which can be detected and quantified on MRI[8],[9]. Further diagnostic procedures include neuropsychological and neurological tests, doppler-sonography and computer tomography which are primarily used to evaluate the clinical impact of CSVD[6],[8],[10]. In addition, several contraindications preclude MRI in a considerable number of patients.

The retina is much easier accessible for imaging and allows for the non-invasive, high-resolution assessment of neuronal tissue using e.g. optical coherence tomography (OCT)[11],[12]. Given the common embryological origin and the common blood supply of both organs through the internal carotid artery, one might expect changes in the retina in CSVD and in fact, peripapillary retinal nerve fiber layer (pRNFL) thickness was found to be decreased in patients with a hereditary form of CSVD[13],[14]. Furthermore, defects of the RNFL appeared to be associated with WML on fundus photographs[15].

Therefore, we here assessed the association of WML on MRI with structural OCT parameters and provide information on the extend and characteristics of macular and optic disc changes in all retinal layers in CSVD to identify markers, which might help to detect this disease at an earlier stage.

Results

36 eyes of 36 participants (27 participants with CSVD and 9 controls) were included in the analysis (Table 1). After screening of 62 individuals initially, 26 subjects were excluded due to retinal pathology (n = 18 subjects), age (n = 7 controls could not be age-matched within 5 years to patients), cerebral WML other than CSVD (n = 1) and poor OCT image quality (n = 2 scans). 19% of our participants were classified as cognitively impaired. 14 participants (39%) were imaged with a 1.5 T MRI device and 22 participants (61%) with 3 T MRI device (Table 1).

Table 1 Demographic variables and imaging parameters of patients and controls.

Total

CSVD

controls

Age matched CSVD

P1*

P2*

Gender (m/f)

15/21

12/15

3/6

4/5

0.641

0.730

MRI (1.5 T/3 T)

22/14

17/10

5/4

6/3

0.747

0.730

Fazekas (score 0/1/2/3)

9/14/10/3

0/14/10/3

9/0/0/0

0/5/4/0

Fazekas (median; IQR)

1; 2

1; 1

0;0

1; 1

< 0.001

< 0.001

Age (years)

63 ± 10

65 ± 11

57 ± 5

57 ± 4

0.073

1.000

MoCA

25 ± 4

25 ± 4

25 ± 3

26 ± 3

0.971

0.436

Cognitively impaired49

19%

22%

11%

11%

WMRI

0.408 ± 0.663

0.536 ± 0.724

0.025 ± 0.027

0.232 ± 0.292

< 0.001

0.006

NOL

14 ± 9

17 ± 9

6 ± 6

13 ± 9

< 0.001

0.031

Total retina volume (mm3)

2.32 ± 0.01

2.31 ± 0.11

2.36 ± 0.07

2.31 ± 0.08

0.101

0.136

Values are mean ± SD and the volume of the retina corresponds to the foveal and parafoveal volumes (3-mm-circle). *Mann–Whitney-U-test was performed to compare the groups. P1, comparison between all patients and controls; P2, comparison between age matched patients and control. Significant results (p < 0.05) are displayed in bold. CSVD, patients with cerebral small vessel disease; MRI, device used for MRI imaging; 1.5 T, Philips Ingenia 1.5 T; 3 T, Achieva TX 3 T, m, male; f, female; Fazekas, Fazekas score; IQR, interquartile range; MoCA, Montreal Cognitive Assessment; WMRI, white matter lesions volume ratio index; NOL, number of white matter lesions.

As expected, patients with CSVD had significantly more WML (p < 0.001) and higher WML volume ratio index (WMRI) (p < 0.0001) compared to control participants. However, the patient group was noticeably older than the control group which is why we performed an age-matched subgroup analysis (see below). The ganglion cell layer (GCL) volume was significantly lower in patients with CSVD compared to controls (0.31 ± 0.04 versus 0.34 ± 0.02, p = 0.032). Neither the other OCT parameters nor the Montreal Cognitive Assessment (MoCA) score were significantly different between patients and controls. In the receiver operating characteristic (ROC) analysis, the GCL volume was significantly associated with CSVD disease status (AUC 0.743; 95%-CI 0.578, 0.908; after adjusting for age: AUC 0.790; 95%-CI 0.641, 0.939). The MoCA-score was not associated with presence of CSVD (AUC 0.506; 95%-CI, 0.302, 0.701).

Age-matched cases and controls

In a subgroup analysis of age-matched CSVD cases (Fazekas > 0) with controls (Fazekas = 0; see Table 1) we found that GCL volume was significantly reduced in patients with CSVD compared to age-matched controls (Table 2). In the analysis of the individual retinal sectors, the parafoveal nasal, inferior and superior volumes of the GCL were significantly reduced in CSVD compared to controls (Table 2).

Table 2 Comparison of structural retinal parameters between patients with cerebral small vessel disease and age-matched controls.

Parameter

Controls

CSVD

P*

GCL (mm3)

0.34 ± 0.02

0.30 ± 0.02

0.008

Foveal

0.01 ± 0.00

0.01 ± 0.00

0.730

Pf. nasal

0.08 ± 0.01

0.07 ± 0.00

0.014

Pf. inferior

0.08 ± 0.01

0.07 ± 0.01

0.019

Pf. temporal

0.08 ± 0.00

0.07 ± 0.01

0.063

Pf. superior

0.08 ± 0.00

0.07 ± 0.01

0.011

IPL (mm3)

0.28 ± 0.02

0.27 ± 0.02

0.094

INL (mm3)

0.27 ± 0.02

0.27 ± 0.02

1.00

OPL (mm3)

0.22 ± 0.06

0.20 ± 0.02

0.340

ONL (mm3)

0.51 ± 0.06

0.55 ± 0.03

0.094

RPE (mm3)

0.11 ± 0.02

0.10 ± 0.02

0.387

pRNFL (µm)

75 ± 6

72 ± 4

0.222

MRW (µm)

341 ± 66

333 ± 65

0.796

Values are mean ± SD and the volumes of the macular layers correspond to the foveal and parafoveal volumes (3-mm-circle). *Mann–Whitney-U-test was performed to compare the two groups. Significant results (p < 0.05) are displayed in bold. CSVD, patients with cerebral small vessel disease; GCL, ganglion cell layer; pf., parafoveal; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium; pRNFL, peripapillary retinal nerve fiber layer; MRW, Bruch's membrane opening-minimum rim width.

Associations of MRI biomarkers with OCT parameters

In a subgroup analysis of CSVD cases only, the WMRI was associated with an increase in volume of the foveal outer plexiform layer (OPL). A decrease of the inner plexiform layer (IPL), the pRNFL and Bruch's membrane opening-minimum rim width (MRW) were significantly associated with a higher WMRI (Table 3 and Supplementary Table 1). After adjusting for age, an increase in the foveal OPL and a decrease in the peripapillary MRW and pRNFL were significantly associated with a higher WMRI (Table 3 and Supplementary Table 1). In age-adjusted multivariable linear regression using backward elimination, foveal OPL volume (β = 81.799; 95%-CI 21.927, 141.671; p = 0.01), temporal pRNFL thickness (β = − 0.021; 95%-CI − 0.039, − 0.002; p = 0.033) and age (β = 0.032; 95%-CI 0.017, 0.047; p < 0.001) remained associated with WMRI.

Table 3 Results of linear regression of structural retinal parameters and white matter lesions volume ratio index in patients with cerebral small vessel disease.

Structural retinal parameter

WMRI association

WMRI association, age adjusted

β [95%-CI]

p

β [95%-CI]

p

IPL

Pf. nasal

− 45.261 [− 86.436, − 4.085]

0.033

27.364 [61.017, 6.289]

0.106

Pf. inferior

− 31.918 [− 59.769, − 4.068]

0.026

21.373 [43.621, 0.874]

0.059

OPL

Foveal

137.950 [62.956, 212.944]

0.001

101.841 [40.874, 162.808]

0.002

pRNFL

Temporal

− 0.032 [− 0.060, − 0.005]

0.024

− 0.029 [− 0.049, − 0.009]

0.007

PMB

− 0.038 [− 0.075, − 0.001]

0.042

− 0.039 [− 0.064, − 0.013]

0.005

MRW

Nasal

− 0.003 [− 0.007, 0.000]

0.044

0.002 [0.005, 0.001]

0.234

Nasal inferior

− 0.004 [− 0.007, 0.000]

0.030

− 0.003 [− 0.005, 0.000]

0.024

Temporal inferior

− 0.004 [− 0.008, − 0.001]

0.017

− 0.003 [− 0.006, − 0.001]

0.016

PMB

− 0.004 [− 0.007, 0.000]

0.033

0.002 [0.005, 0.001]

0.209

Nasal superior

− 0.004 [− 0.007, − 0.001]

0.018

0.002 [0.005, 0.000]

0.087

Associations between retinal parameters and WMRI were assessed using linear regression. Model 1: univariate regression, Model 2: multivariable regression adjusted for age. Significant associations (p < 0.05) are displayed in bold. In this table, only parameters are listed with a p value < 0.05 in at least one linear regression model. Further results are listed in the supplement. The volumes of the macular layers correspond to the foveal and parafoveal volumes (3-mm-circle). WMRI, white matter lesions volume ratio index; β, standardized coefficient; CI, confidence interval; IPL, inner plexiform layer; pf., parafoveal; OPL, outer plexiform layer; pRNFL, peripapillary retinal nerve fiber layer; PMB, papillo-macular bundle; MRW, Bruch's membrane opening-minimum rim width.

Most of the peripapillary MRW-locations and both peripapillary (pRNFL) and macular layers (IPL, outer nuclear layer, OPL) were significantly associated with the number of WML (NOL) (Table 4 and Supplementary Table 2). After adjusting for age, GCL, IPL and OPL volumes as well as MRW and pRNFL thickness were significantly associated with NOL (Table 4 and Supplementary Table 2). In stepwise multivariate linear regression foveal GCL volume (β = − 1266.561; 95%-CI − 1901.908, − 631.215; p < 0.001), temporal inferior MRW (β = − 0.111; 95%-CI − 0.159, − 0.062; p < 0.001), temporal MRW (β = 0.057; 95%-CI 0.004, 0.109; p = 0.037) and age (β = 0.547; 95%-CI 0.349, 0.746; p < 0.001) remained associated with NOL.

Table 4 Results of linear regression of structural retinal parameters and number of white matter lesions in patients with cerebral small vessel disease.

Structural retinal parameter

NOL association

NOL association, age adjusted

β [95%-CI]

p

β [95%-CI]

p

Total retina

Pf. superior

− 159.270 [− 316.458, − 2.082]

0.047

− 99.825 [− 243.197, 43.547]

0.164

GCL

Total volume

− 72.052 [− 159.997, 15.894]

0.104

− 72.245 [− 144.055, − 0.435]

0.049

Foveal

− 591.667 [− 1671.649, 488.315]

0.270

− 874.843 [− 1743.724, − 5.961]

0.049

Pf. nasal

− 269.435 [− 635.884, 97.014]

0.142

− 306.899 [− 602.325, − 11.473]

0.042

IPL

Pf. nasal

− 693.590 [− 1237.220, − 149.959]

0.014

− 500.646 [− 993.331, − 7.961]

0.047

Pf. inferior

− 452.976 [− 827.535, − 78.417]

0.020

− 336.222 [− 668.912, − 3.533]

0.048

OPL

Foveal

1550.000 [442.428, 2657.572]

0.008

1129.675 [112.316, 2147.033]

0.031

Pf. superior

412.534[110.271, 714.797]

0.009

268.754 [− 25.311, 562.819]

0.071

ONL

Pf. superior

− 325.122 [− 557.611, − 92.634]

0.008

− 173.958 [− 433.211, 85.294]

0.179

pRNFL

N/T

15.701 [− 2.940, 34.341]

0.095

15.711 [0.737, 30.685]

0.041

Temporal

− 0.475 [− 0.853, − 0.097]

0.016

− 0.432 [− 0.736, − 0.128]

0.007

PMB

− 0.481 [− 0.993, 0.030]

0.064

− 0.487 [− 0.893, − 0.081]

0.021

Temporal superior

− 0.226 [− 0.443, − 0.008]

0.043

− 0.189 [− 0.371, − 0.008]

0.041

MRW

Total

− 0.074 [− 0.128, − 0.020]

0.009

− 0.055 [− 0.103, − 0.007]

0.027

Nasal

− 0.068 [− 0.110, − 0.026]

0.003

− 0.050 [− 0.089, − 0.010]

0.016

Nasal inferior

− 0.067 [− 0.108, − 0.026]

0.002

− 0.059 [− 0.092, − 0.026]

0.001

Temporal inferior

− 0.076 [− 0.120, − 0.031]

0.002

− 0.065 [− 0.101, − 0.028]

0.001

Temporal

− 0.067 [− 0.116, − 0.019]

0.009

− 0.048 [− 0.092, − 0.003]

0.039

PMB

− 0.063 [− 0.107, − 0.018]

0.008

− 0.042 [− 0.085, 0.000]

0.050

Temporal superior

− 0.054 [− 0.105, − 0.004]

0.035

− 0.039 [− 0.083, 0.006]

0.085

Nasal superior

− 0.065 [− 0.109, − 0.020]

0.006

− 0.046 [− 0.087, − 0.005]

0.029

Associations between retinal parameters and NOL were assessed using linear regression. Model 1: univariate regression, Model 2: multivariable regression adjusted for age; significant associations (p < 0.05) are displayed in bold. In this table, only parameters are listed with a p value < 0.05 in at least one linear regression model. Further results are listed in the supplement. The volumes of the macular layers correspond to the foveal and parafoveal volumes (3-mm-circle). NOL, number of white matter lesions; β, standardized coefficient; CI, confidence interval; pf., parafoveal; GCL, ganglion cell layer; IPL, inner plexiform layer; OPL, outer plexiform layer; ONL, outer nuclear layer; pRNFL, peripapillary retinal nerve fiber layer; N/T, ratio nasal to temporal; PMB, papillo-macular bundle; MRW, Bruch's membrane opening-minimum rim width.

Discussion

In this study we found that peripapillary and macular OCT parameters, most prominently the GCL, were associated with both the extent of CSVD lesions on MRI as well as reduced in comparison to controls without CSVD. These results support a relationship of retinal structural parameters and cerebral changes in CSVD and may be useful in the detection and staging of CSVD. Further studies are needed to better characterize this relationship.

Our findings are in agreement with published studies. Aggarwal et al. reported a significant reduction of ganglion cells in patients with chronic non‐arteritic anterior ischemic optic neuropathy[16]. This is consistent with the observation of GCL reduction in other diseases associated with ischemia like diabetes and retinal vein occlusion[17],[18]. Vascular factors also play an important role in the pathogenesis of many neurodegenerative diseases such as multiple sclerosis, Alzheimer's disease and Parkinson's disease, in all of which a significant GCL difference between cases and controls has been described[19]–[29]. Nevertheless, the use of retinal GCL volume as a biomarker in CSVD needs to be investigated in further studies.

Interestingly, we found an OPL volume increase in association with a higher WMRI and a higher NOL. OPL thickening could be found as well in two studies which compared patients with Parkinson's disease to controls[30],[31]. Other studies could not confirm this finding[32],[33]. In multiple sclerosis and Alzheimer's disease, the OPL has been reported to be decreased or unchanged in patients compared to controls, whereas other layers like the inner and outer nuclear layer have been reported to be significantly thicker in patients with neurodegenerative diseases[34]–[36]. Explanations offered for increases in thickness or volume include local inflammation, ischemia and cellular movements[35]. Ischemia has been demonstrated to lead to a significantly thickened OPL in diabetic retinopathy[37].

The absence of any difference in pRNFL thickness between patients and controls in our study is in contrast to two studies which investigated patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) and reported RNFL thickness to be reduced compared to controls[13],[14]. Some of the included CADASIL-patients showed more severe symptoms such as migraine-like episodes with aphasia and hemiparesis[13]. This may explain our different results as patients and controls were largely clinically silent and not cognitively affected in our study. However our results on pRNFL measurements are in agreement with a recent study of Lee et al. on vascular changes in CSVD patients who did not find any differences between cases and controls[38]. In addition to Lee et al., we also investigated structural retinal parameters and found a significant association between the decrease of pRNFL thickness and an increase of WML. Similar results were obtained in a Korean study, which could demonstrate associations between white matter lesions and RNFL defects visible on fundus photographs in a large population[15]. Using MRW, which quantifies pRNFL thickness whilst taking local anatomic conditions (i.e. Bruch's Membrane Opening, BMO) into account, we found significant associations with both WMRI and the NOL which were in keeping with expectations for pRNFL thickness based on published literature[36],[39],[40]. MRW is not widely used yet, but promises to be a useful parameter with theoretically better reproducibility compared to pRNFL thickness[41].

The strengths of this study include the thorough screening for concurrent neurological or ocular comorbidities, the use of high-resolution MRI, a complete ophthalmic assessment, the use of state-of-the-art high-resolution SD-OCT imaging including novel read-outs corrected for ocular anatomy such as MRW and the use of standardized and published automated image analysis for both MRI and OCT. To date, this study is the first to investigate structural retinal changes considering all layers assessed by OCT in patients with CSVD after few studies assessed single-layer structural changes or structural and flow changes within the retinal vasculature[38],[42]–[44]. The limitations of our study include foremost its relatively small sample size. As our study was designed as an exploratory study, confirmatory studies with larger sample sizes are needed. Different MRI devices and sequences were used in a clinical routine setting due to different medical indications for MRI imaging which could have an influence on the comparability and applicability to a population-based setting. In order to ensure comparability we used the LST- lesion prediction algorithm (LPA) segmentation method, which has proven good performances within and across scanners for white matter hyperintensity segmentation in a multicenter dataset[45]. Inaccuracies may have occurred due to the use of 2D instead of 3D data sets for the LST-LPA[46]. Nevertheless, the LST-LPA has already been demonstrated to be valid and reliable in 2D data sets[47].

Non-neurological and non-ocular comorbidities were not assessed which might have affected our findings. One patient had a meningioma which had no influence on the evaluation of the Fazekas score or on the lesion segmentation and assumingly did not affect OCT measurements based on its localization. A further limitation is the time lag between MR-and OCT-imaging which might have led to an underestimation of effect size as cerebral CVSD lesions might have progressed in the meantime. We did not correct for multiple testing as this was an exploratory study, which might lead to spurious associations. Thus, any findings need confirmation in additional studies.

In conclusion, several retinal structural changes are present in CSVD patients, related to the extent of the cerebral changes and independent of their age. Many of these changes are unspecific in isolation but future studies may succeed in identifying a specific profile of retinal changes able to aid in the detection and monitoring of CSVD.

Methods

Participants

A total of 62 subjects (44 patients with CSVD and 18 control participants without CSVD or ocular diseases) were recruited from a database of the Department of Neurology at the University Hospital Bonn for this case–control study. All subjects had undergone cerebral MRI for clinical indications. The study followed the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital Bonn (consecutive Number: 281/17). Written informed consent was obtained from all participants.

Potential participants were identified using an internal MRI database. The search algorithm included "MRI obtained between 01/01/2017 and 05/31/2019", as well as the keywords "headache," "dizziness," "syncope," "paresthesia," "exclusion of microembolization," and "exclusion of metastases".

Exclusion criteria were any eye diseases including glaucoma and retinal diseases, any opacity of the optical media interfering with retinal imaging, malignancy, major stroke, larger intracranial lesions or structural anomalies affecting the MRI analysis.

All participants underwent cognitive testing using the MoCA[48]. A result of 23 or more points was classified as cognitively normal[49].

MRI imaging

For the clinically indicated 1.5 or 3 T MRI-Imaging (Philips Ingenia 1.5 T and Achieva TX 3 T; Philips Healthcare, Best/The Netherlands) an 8-channel head coil was used.

Axial whole-brain 2D fluid-attenuated inversion recovery (FLAIR) images with a slice thickness of 6 mm, no gap and an echo time of 140 ms were evaluated for all patients. The FLAIR sequence of the 1.5 T MRI scanner had a matrix of 352 × 352, a repetition time of 11 s and an inversion time of 2800 ms. The corresponding sequence of the 3 T MRI scanner had a matrix of 512 × 512, a repetition time of 12 s and an inversion time of 2850 ms.

All patients and controls were independently evaluated and clinically diagnosed by two board certified neuroradiologists, based on the microvascular leukoencephalopathy score according to Fazekas et al.[50] The score describes the quantity of white matter T2 hyperintense lesions. A score of 0 refers to the absence of periventricular or deep WML, a score of 1 to punctate foci or pencil thin lesions. The lesions form a smooth periventricular "halo" or become confluent at a score of 2. A Fazekas score of 3 describes large confluent and irregular lesion areas, which extend periventricular into the deep white matter.

The lesions were automatically segmented with the LST Toolbox (version 2.0.15 for SPM12)[51]. LPA was used to calculate NOL and volume of the WML in the 2D data sets. The algorithm was developed for and trained on the segmentation of lesions in multiple sclerosis[52],[53]. Further studies have already used the LST for other diseases like Amyotrophic Lateral Sclerosis and diabetes mellitus[54],[55]. The algorithm only needs FLAIR sequences for the analysis. It consists of a binary classifier in the form of a logistic regression model and uses a lesion belief map and a spatial covariate, which assesses the changes in lesion probability for each voxel. In new images, the algorithm evaluates the voxel specific lesion probability, based on the previous parameters of the model, and uses the results for the lesion segmentation (Fig. 1)[53]. The automated segmentation of volume and NOL was manually checked for accuracy. Following this, the degree of lesions of each subject was related to the total intracranial volume (TIV). The 2D FLAIR images were also used to calculate the TIV. First, the LST toolbox was used to annotate the WML. The subsequent calculation of the TIV was performed with SPM12. We used the standard segmentation algorithm for automatic segmentation of the white and grey matter and CSF. The volumes of the three tissue classes were added to the TIV. The volume ratio of WML was calculated from the ratio of lesion volume to TIV. To get a better overview, the results were multiplied by 100, which gave the volume of WML as a percentage of the intracranial volume (WMRI).

Graph: Figure 1 T2 FLAIR images from a 75-year old participant with hyperintense lesions (Fazekas 3) due to cerebral small vessel disease. (A) T2 FLAIR image showing multiple hyperintense white matter lesions. (B) Results of the white matter lesions segmentation using the lesion prediction algorithm. The white matter lesions detected by the algorithm are presented in red-yellow.

Ophthalmic assessment and OCT Imaging

All participants underwent a complete ophthalmic assessment including retinal and optic nerve head imaging using spectral domain OCT-imaging. The time interval between MRI and ophthalmic assessment was 9,5 months at median (range: 6 weeks to 20 months). Participants were imaged with non-dilated pupils, using the same OCT-device (Spectralis HRA + OCT, version 6.5.4.0, Heidelberg Engineering, Heidelberg, Germany). Reporting of OCT imaging followed the APOSTEL 2.0 guidelines[56]. OCT-imaging was performed by two trained operators (SML, CFG).

A macular volume scan (121 horizontal B-Scans, 25 frames, 20° × 25°), and a BMO scan (3.5 mm, 4.1 mm, and 4.7 mm diameter circular scans with 100 frames and automatic placement and 24 radial scans with 25 frames each) of the optic nerve head were acquired (Fig. 2). The integrated automatic real-time function adjusts for eye movement and offers a high resolution and reproducibility[57],[58]. The BMO-scan combines the imaging of pRNFL (Fig. 2B) and the MRW (Fig. 2C). The MRW describes the anatomy of the optic nerve head and quantifies the minimum distance between the inner limiting membrane and the BMO (Fig. 2)[59]. It has been most widely used to capture pathological changes of the optic nerve head in e.g. glaucoma[41],[60].

Graph: Figure 2 Optical coherence tomography-images of 75-year old participant. (A) Macular scan—different macular layers are segmented; (B) RNFL-scan—the peripapillary retinal nerve fiber layer (pRNFL) is segmented; (C) BMO-scan—the arrows show the Bruch's membrane opening-minimum rim width (MRW). RNFL retinal nerve fiber layer, GCL ganglion cell layer, IPL inner plexiform layer, INL inner nuclear layer, OPL outer plexiform layer, ONL outer nuclear layer, RPE retinal pigment epithelium.

The right eye of each patient was chosen for analysis except cases in whom any of the exclusion criteria applied for the right eye. In those cases, the left eye was chosen. OCT images with poor quality (i.e. < 20 dB single strength) or motion artifacts were excluded, as assessed by three graders (SML, JHT, CAT). Automated segmentation was performed, using the Heidelberg Eye Explorer (HEYEX 2, Heidelberg Engineering, Heidelberg, Germany). The automated segmentation boundaries of the individual layers (Fig. 2A), the pRNFL (Fig. 2B) and the MRW (Fig. 2C) were manually verified for accuracy and corrected if needed. The volumes were measured using the Early Treatment Diabetic Retinopathy Study grid[61]. We added the foveal and parafoveal volumes and used the 3 mm-circle-volumes as macular parameters. The outermost circle of the BMO scan (4.7 mm diameter) was used for pRNFL-analysis.

Statistical analysis

Data analysis was performed with IBM SPSS Statistics (version 26.0). Descriptive statistics included mean scores which were compared using the Mann–Whitney-U-test for the overall cohort and for the age-matched sub-cohort (± 5 years).

Receiver operating characteristic (ROC) analysis with and without age adjustment was performed to determine the sensitivities of retinal parameters and MoCA score to detect CSVD (based on the Fazekas score) in our cohort. Because of a positive Pearson correlation coefficient between the OPL and the WMRI, the ROC-analysis for the OPL was performed with inversed OPL values. Binary logistic regression analysis was performed to determine the regression coefficients and the constant for age adjustment. Age and other significant parameters of the non-age-adjusted ROC analysis were used as independent variables in age-adjusted ROC analysis. Because of not normally-distributed WMRI residuals, WMRI values were logarithmically transformed for parametric statistical analyses.

In a subgroup analysis of all participants with CSVD, to whom none of the exclusion criteria applied, we investigated associations between MRI (WMRI, NOL) and OCT parameters using linear regression analysis. Multivariable regression models included parameters which were significantly associated in age-adjusted linear regressions and were calculated using backward elimination. If two dependent OCT-parameters correlated > 0.80 according to Pearson, only the one with a stronger correlation was included in the model to avoid multicollinearity.

The global statistical significance level was 0.05. This study followed STROBE checklist for observational research[62].

Acknowledgements

This research was supported by funding of the German Scholars Organization/Else Kröner Fresenius Stiftung (GSO/EKFS 16) to RF and BONFOR GEROK Program, Faculty of Medicine, University of Bonn, Grant No. O-137.0028 to MWMW. All images included in this paper were created by the authors themselves.

Author contributions

R.P.F. and G.C.P. designed this study. S.M.L., C.F.G., C.K. and V.C.W.K. acquired the data. S.M.L., J.H.T., C.K., V.C.W.K., R.P.F., C.A.T., G.N.T., C.B. and M.W.M.W. analyzed and interpreted the data. S.M.L., J.H.T. and R.P.F. drafted the initial manuscript. C.F.G., C.K., V.C.W.K., C.A.T., G.N.T., C.B., M.W.M.W. and G.C.P. critically revised the manuscript. All authors approved the final manuscript and agreed to be accountable for all aspects of the work.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Data availability

The data that support the findings of this study are included in the Supplement. Further data are available from the corresponding author upon reasonable request.

Competing interests

SML, JHT, CFG, CAT, GNT: Heidelberg Engineering, Optos, Carl Zeiss Meditec, CenterVue (devices). CB, CK, VCK: none. MWMW: Heidelberg Engineering, Optos, Carl Zeiss Meditec, CenterVue, D-EYE Srl (devices); DigiSight Technologies (travel support); Heine Optotechnik (research funding, devices, travel reimbursement, consultant); Eyenuk Inc. (free analysis); ASKIN & CO GmbH (travel reimbursement, honoraria); Berlin-Chemie AG (grant, travel reimbursements). GCP: Bayer, Boehringer Ingelheim, Pfizer, BMS (sponsoring). RPF: Bayer, Novartis, Santen, Opthea, Novelion, Santhera, Inositec, Alimera, Retina Implant, Allergan, Boehringer Ingelheim (consultant); Bayer, Ellex, Alimera (research funding); Heidelberg Engineering, Optos, Carl Zeiss Meditec, CenterVue (devices).

Supplementary Information

Graph: Supplementary Information.

Abbreviations

• BMO

  • Bruch's membrane opening

• CADASIL

  • Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy

• CSVD

  • Cerebral small vessel disease

• FLAIR

  • Fluid-attenuated inversion recovery

• GCL

  • Ganglion cell layer

• INL

  • Inner nuclear layer

• IPL

  • Inner plexiform layer

• LPA

  • Lesion prediction algorithm

• MoCA

  • Montreal cognitive assessment

• MRW

  • Bruch's membrane opening-minimum rim width

• NOL

  • Number of white matter lesions

• OCT

  • Optical coherence tomography

• ONL

  • Outer nuclear layer

• OPL

  • Outer plexiform layer

• PMB

  • Papillo-macular bundle

• pRNFL

  • Peripapillary retinal nerve fiber layer

• ROC

  • Receiver operating characteristic

• RPE

  • Retinal pigment epithelium

• TIV

  • Total intracranial volume

• WML

  • White matter lesions

• WMRI

  • White matter lesions volume ratio index
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-13312-z.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References 1 Arnoldussen IAC, Gustafson DR, Leijsen EMC, de Leeuw F-E, Kiliaan AJ. Adiposity is related to cerebrovascular and brain volumetry outcomes in the RUN DMC study. Neurology. 2019; 93: e864-e878. 31363056. 10.1212/WNL.0000000000008002 2 de Leeuw FE. Prevalence of cerebral white matter lesions in elderly people: A population based magnetic resonance imaging study. The Rotterdam Scan Study. J. Neurol. Neurosurg. Psychiatry. 2001; 70: 9-14. 11118240. 1763449. 10.1136/jnnp.70.1.9 3 Pantoni L. Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010; 9: 689-701. 20610345. 10.1016/S1474-4422(10)70104-6 4 Cees De Groot J. Cerebral white matter lesions and cognitive function: The Rotterdam scan study. Ann. Neurol. 2000; 47: 145-151. 10.1002/1531-8249(200002)47:2<145:AID-ANA3>3.0.CO;2-P 5 van der Flier WM. Small vessel disease and general cognitive function in nondisabled elderly: The LADIS study. Stroke. 2005; 36: 2116-2120. 2005astro.ph.2116F. 16141425. 10.1161/01.STR.0000179092.59909.42 6 Li Q. Cerebral small vessel disease. Cell Transplant. 2018; 27: 1711-1722. 30251566. 6300773. 10.1177/0963689718795148 7 Launer LJ. Epidemiology of white matter lesions. Top. Magn. Resonance Imaging TMRI. 2004; 15: 365-367. 10.1097/01.rmr.0000168216.98338.8d 8 Wardlaw JM. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013; 12: 822-838. 23867200. 3714437. 10.1016/S1474-4422(13)70124-8 9 Blair GW, Hernandez MV, Thrippleton MJ, Doubal FN, Wardlaw JM. Advanced neuroimaging of cerebral small vessel disease. Curr. Treat. Opt. Cardiovasc. Med. 2017; 19: 56. 10.1007/s11936-017-0555-1 Salvadori E, Brambilla M, Cova I, Pomati S, Pantoni L. Cognitive evaluation in cerebral small vessel disease: Towards an evidence-based identification of the reference standards. Part 1. A systematic review and qualitative data synthesis. J. Neurol. 2020. 10.1007/s00415-020-10262-2. 33048216 Baker ML, Hand PJ, Wang JJ, Wong TY. Retinal signs and stroke: Revisiting the link between the eye and brain. Stroke. 2008; 39: 1371-1379. 18309171. 10.1161/STROKEAHA.107.496091 Jindahra P, Hedges TR, Mendoza-Santiesteban CE, Plant GT. Optical coherence tomography of the retina: Applications in neurology. Curr. Opin. Neurol. 2010; 23: 16-23. 20009925. 10.1097/WCO.0b013e328334e99b Parisi V. Reduction of optic nerve fiber layer thickness in CADASIL. Eur. J. Neurol. 2007; 14: 627-631. 1:STN:280:DC%2BD2szislyluw%3D%3D. 17539939. 10.1111/j.1468-1331.2007.01795.x Rufa A. Retinal nerve fiber layer thinning in CADASIL: An optical coherence tomography and MRI study. Cerebrovasc. Dis. (Basel, Switzerland). 2011; 31: 77-82. 10.1159/000321339 Kim M. Retinal nerve fiber layer defect and cerebral small vessel disease. Investig. Ophthalmol. Vis. Sci. 2011; 52: 6882-6886. 10.1167/iovs.11-7276 Aggarwal D, Tan O, Huang D, Sadun AA. Patterns of ganglion cell complex and nerve fiber layer loss in nonarteritic ischemic optic neuropathy by Fourier-domain optical coherence tomography. Investig. Ophthalmol. Vis. Sci. 2012; 53: 4539-4545. 10.1167/iovs.11-9300 Lange J, Hadziahmetovic M, Zhang J, Li W. Region-specific ischemia, neovascularization and macular oedema in treatment-naïve proliferative diabetic retinopathy. Clin. Exp. Ophthalmol. 2018; 46: 757-766. 29412501. 10.1111/ceo.13168 Shin Y-I. Changes in peripapillary microvasculature and retinal thickness in the fellow eyes of patients with unilateral retinal vein occlusion: An OCTA study. Investig. Ophthalmol. Vis. Sci. 2019; 60: 823-829. 10.1167/iovs.18-26288 Nelson AR, Sweeney MD, Sagare AP, Zlokovic BV. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. Biochem. Biophys. Acta. 2016; 1862: 887-900. 1:CAS:528:DC%2BC2MXitVGrtrfJ. 26705676 Di Marco LY. Vascular dysfunction in the pathogenesis of Alzheimer's disease—A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol. Dis. 2015; 82: 593-606. 26311408. 10.1016/j.nbd.2015.08.014. 1:CAS:528:DC%2BC2MXhsFeju7bM Syrimi ZJ. Arterial spin labelling detects posterior cortical hypoperfusion in non-demented patients with Parkinson's disease. J. Neural Transm. 2017; 124: 551-557. 1:CAS:528:DC%2BC2sXjvFWnsbY%3D. 28271290. 10.1007/s00702-017-1703-1 Fernández-Seara MA. Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI. Neuroimage. 2012; 59: 2743-2750. 22032942. 10.1016/j.neuroimage.2011.10.033 Ortiz GG. Role of the blood–brain barrier in multiple sclerosis. Arch. Med. Res. 2014; 45: 687-697. 1:CAS:528:DC%2BC2MXis1akt70%3D. 25431839. 10.1016/j.arcmed.2014.11.013 Minagar A, Alexander JS. Blood–brain barrier disruption in multiple sclerosis. Mult. Scler. 2003; 9: 540-549. 1:CAS:528:DC%2BD3sXhtVSqtr3M. 14664465. 10.1191/1352458503ms965oa Syc SB. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2012; 135: 521-533. 22006982. 10.1093/brain/awr264 Walter SD. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. 2012; 119: 1250-1257. 22365058. 10.1016/j.ophtha.2011.11.032 Colligris P, Perez de Lara MJ, Colligris B, Pintor J. Ocular manifestations of Alzheimer's and other neurodegenerative diseases: The prospect of the eye as a tool for the early diagnosis of Alzheimer's disease. J. Ophthalmol. 2018; 2018: 8538573. 30151279. 6091327 Doustar J, Torbati T, Black KL, Koronyo Y, Koronyo-Hamaoui M. Optical coherence tomography in Alzheimer's disease and other neurodegenerative diseases. Front. Neurol. 2017; 8: 701. 29312125. 5742098. 10.3389/fneur.2017.00701 Satue M. Retinal and choroidal changes in patients with Parkinson's disease detected by swept-source optical coherence tomography. Curr. Eye Res. 2018; 43: 109-115. 29111842. 10.1080/02713683.2017.1370116 Pilat A. In vivo morphology of the optic nerve and retina in patients with Parkinson's disease. Investig. Ophthalmol. Vis. Sci. 2016; 57: 4420-4427. 10.1167/iovs.16-20020 Chorostecki J. Characterization of retinal architecture in Parkinson's disease. J. Neurol. Sci. 2015; 355: 44-48. 26071887. 10.1016/j.jns.2015.05.007 Garcia-Martin E. Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. Am. J. Ophthalmol. 2014; 157: 470-478.e2. 24315296. 10.1016/j.ajo.2013.09.028 Chrysou A, Jansonius NM, van Laar T. Retinal layers in Parkinson's disease: A meta-analysis of spectral-domain optical coherence tomography studies. Parkinsonism Relat. Disord. 2019; 64: 40-49. 31054866. 10.1016/j.parkreldis.2019.04.023 Lambe J, Murphy OC, Saidha S. Can optical coherence tomography be used to guide treatment decisions in adult or pediatric multiple sclerosis?. Curr. Treat. Opt. Neurol. 2018; 20: 9. 10.1007/s11940-018-0493-6 Salobrar-García E. Changes in visual function and retinal structure in the progression of Alzheimer's disease. PLoS ONE. 2019; 14. 31415594. 6695171. 10.1371/journal.pone.0220535. 1:CAS:528:DC%2BC1MXhvFamtbfM Petzold A. Retinal layer segmentation in multiple sclerosis: A systematic review and meta-analysis. Lancet Neurol. 2017; 16: 797-812. 28920886. 10.1016/S1474-4422(17)30278-8 Reznicek L. In vivo characterization of ischemic retina in diabetic retinopathy. Clin. Ophthalmol. (Auckland, N.Z.). 2010; 5: 31-35. 10.2147/OPTH.S13850 Lee J-Y. Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases. Alzheimer's Res. Ther. 2020; 12: 73. 10.1186/s13195-020-00638-x. 1:CAS:528:DC%2BB3cXhtF2jt7%2FL Thomson KL, Yeo JM, Waddell B, Cameron JR, Pal S. A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimer's Dement. Diagnosis Assess. Dis. Monit. 2015; 1: 136-143 Yu J. Retinal nerve fiber layer thickness changes in Parkinson disease: A meta-analysis. PLoS ONE. 2014; 9. 2014PLoSO.985718Y. 24465663. 3897496. 10.1371/journal.pone.0085718. 1:CAS:528:DC%2BC2cXlsVamsbY%3D Enders P. Bruch's membrane opening-based optical coherence tomography of the optic nerve head: A useful diagnostic tool to detect glaucoma in macrodiscs. Eye. 2018; 32: 314-323. 1:STN:280:DC%2BC1MvlvFKjtA%3D%3D. 29386616. 5811742. 10.1038/eye.2017.306 Geerling CF. Changes of the retinal and choroidal vasculature in cerebral small vessel disease. Sci. Rep. 2022; 12: 3660. 2022NatSR.12.3660G. 1:CAS:528:DC%2BB38XmtFymtrY%3D. 35256658. 8901619. 10.1038/s41598-022-07638-x Wang X. The vessel density of the superficial retinal capillary plexus as a new biomarker in cerebral small vessel disease: An optical coherence tomography angiography study. Neurol. Sci. 2021; 42: 3615-3624. 33432462. 10.1007/s10072-021-05038-z Abdelhak A. Optical coherence tomography-based assessment of retinal vascular pathology in cerebral small vessel disease. Neurol. Res. Pract. 2020; 2: 13. 1:STN:280:DC%2BB3szot1Wisw%3D%3D. 33324919. 7650138. 10.1186/s42466-020-00062-4 Heinen R. Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. Sci. Rep. 2019; 9: 16742. 2019NatSR.916772H. 31727919. 6856351. 10.1038/s41598-019-52966-0. 1:CAS:528:DC%2BC1MXitFymsLzM Guo C. Intra-scanner and inter-scanner reproducibility of automatic white matter hyperintensities quantification. Front. Neurosci. 2019; 13: 679. 31354406. 6635556. 10.3389/fnins.2019.00679 Gwo C-Y, Zhu DC, Zhang R. Brain white matter hyperintensity lesion characterization in T2 fluid-attenuated inversion recovery magnetic resonance images: Shape, texture, and potential growth. Front. Neurosci. 2019; 13: 353. 31057353. 6477529. 10.3389/fnins.2019.00353 Nasreddine ZS. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 2005; 53: 695-699. 15817019. 10.1111/j.1532-5415.2005.53221.x Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. Int. J. Geriatr. Psychiatry. 2018; 33: 379-388. 28731508. 10.1002/gps.4756 Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am. J. Roentgenol. 1987; 149: 351-356. 1:STN:280:DyaL2s3mslWgsw%3D%3D. 3496763. 10.2214/ajr.149.2.351 LST—Lesion segmentation for SPM | Paul Schmidt—freelance statistician. https://www.statistical-modelling.de/lst.html (2021). Schmidt, P. Bayesian inference for structured additive regression models for large-scale problems with applications to medical imaging. Ph.D. thesis, Ludwig-Maximilians-Universität München (2017). Schmidt P. An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage. 2012; 59: 3774-3783. 22119648. 10.1016/j.neuroimage.2011.11.032 Wirth AM. Value of fluid-attenuated inversion recovery MRI data analyzed by the lesion segmentation toolbox in amyotrophic lateral sclerosis. J. Magn. Resonance Imaging JMRI. 2019; 50: 552-559. 10.1002/jmri.26577 Maldjian JA. Automated white matter total lesion volume segmentation in diabetes. AJNR Am. J. Neuroradiol. 2013; 34: 2265-2270. 1:STN:280:DC%2BC3sfitVynsg%3D%3D. 23868156. 4038900. 10.3174/ajnr.A3590 Aytulun A. APOSTEL 2.0 recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2021; 97: 68-79. 33910937. 8279566. 10.1212/WNL.0000000000012125 Rougier M-B. Retinal nerve fibre layer thickness measured with SD-OCT in a population-based study of French elderly subjects: The Alienor study. Acta Ophthalmol. 2015; 93: 539-545. 25586172. 10.1111/aos.12658 Wolf-Schnurrbusch UEK. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Investig. Ophthalmol. Vis. Sci. 2009; 50: 3432-3437. 10.1167/iovs.08-2970 Reis ASC. Influence of clinically invisible, but optical coherence tomography detected, optic disc margin anatomy on neuroretinal rim evaluation. Investig. Ophthalmol. Vis. Sci. 2012; 53: 1852-1860. 10.1167/iovs.11-9309 Park K-H, Lee J-W, Kim J-M, Nouri-Mahdavi K, Caprioli J. Bruch's membrane opening-minimum rim width and visual field loss in glaucoma: A broken stick analysis. Int. J. Ophthalmol. 2018; 11: 828-834. 29862184. 5957037 Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—An extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology. 1991; 98: 786-806. 10.1016/S0161-6420(13)38012-9 Cuschieri S. The STROBE guidelines. Saudi J. Anaesth. 2019; 13: S31-S34. 30930717. 6398292. 10.4103/sja.SJA_543_18

By S. Magdalena Langner; Jan H. Terheyden; Clara F. Geerling; Christine Kindler; Vera C. W. Keil; Christopher A. Turski; Gabrielle N. Turski; Charlotte Behning; Maximilian W. M. Wintergerst; Gabor C. Petzold and Robert P. Finger

Reported by Author; Author; Author; Author; Author; Author; Author; Author; Author; Author; Author

Titel:
Structural retinal changes in cerebral small vessel disease
Link:
Zeitschrift: Scientific Reports, Jg. 12 (2022-12-01), Heft 1
Veröffentlichung: 2022
Medientyp: unknown
ISSN: 2045-2322 (print)
Schlagwort:
  • genetic structures
  • sense organs
  • eye diseases
Sonstiges:
  • Nachgewiesen in: OpenAIRE
  • Sprachen: English
  • Language: English
  • Rights: OPEN

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -